MCID: LKM002
MIFTS: 72

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia is related to leukemia, acute lymphoblastic and childhood leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 76 Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1600)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 34.2 ABL1 BCR ETV6 FLT3 MIR27A RUNX1
2 childhood leukemia 34.2 ABL1 ETV6 PBX1 RUNX1
3 acute leukemia 34.1 CEBPA ETV6 FLT3 RUNX1
4 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.1 ETV6 FLT3 RUNX1
5 myeloid leukemia 34.0 ABL1 BCR CEBPA ETV6 FLT3 LIF
6 leukemia, chronic myeloid 34.0 ABL1 BCR ETV6 FLT3 HOTAIR RUNX1
7 cytogenetically normal acute myeloid leukemia 34.0 CEBPA FLT3 NPM1
8 acute myeloblastic leukemia without maturation 34.0 FLT3 NPM1
9 chronic myelomonocytic leukemia 34.0 ETV6 FLT3 RUNX1
10 acute myeloblastic leukemia with maturation 34.0 FLT3 NPM1
11 core binding factor acute myeloid leukemia 33.9 CEBPA FLT3 RUNX1
12 acute lymphocytic leukemia 33.9 BCR CDKN2B-AS1 ETV6 RUNX1
13 lymphocytic leukemia 33.8 BCR ETV6 HOTAIR RUNX1
14 lymphoid leukemia 33.8 ETV6 FLT3
15 b-cell childhood acute lymphoblastic leukemia 33.8 ETV6 RUNX1
16 acute promyelocytic leukemia 33.8 CEBPA FLT3 HOTAIRM1 NEAT1 NPM1 PML
17 leukemia, acute lymphoblastic 3 33.6 ABL1 BCR ETV6 FLT3 PBX1 RUNX1
18 precursor t-cell acute lymphoblastic leukemia 33.6 ABL1 BCR ETV6 FLT3 TCL1A
19 b-cell adult acute lymphocytic leukemia 33.6 ABL1 PBX1
20 aleukemic leukemia cutis 33.5 FLT3 NPM1 RUNX1
21 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.4 CEBPA FLT3 RUNX1
22 philadelphia-negative chronic myeloid leukemia 33.4 ABL1 BCR
23 leukemia, acute myeloid 33.2 ABL1 BCR CDKN2B-AS1 CEBPA ETV6 FLT3
24 platelet disorder, familial, with associated myeloid malignancy 33.0 ETV6 RUNX1
25 myelodysplastic syndrome 32.7 ABL1 CEBPA ETV6 FLT3 MLF1 NPM1
26 8p11 myeloproliferative syndrome 32.4 BCR FLT3 RUNX1
27 melanoma 29.3 CDKN2B-AS1 GAS5 HOTAIR HOTAIRM1 MIR27A
28 glioma 29.1 CDKN2B-AS1 GAS5 HOTAIR NEAT1
29 osteogenic sarcoma 29.0 CDKN2B-AS1 GAS5 HOTAIR NEAT1
30 thyroid cancer 28.9 CDKN2B-AS1 GAS5 HOTAIR MLF1 NEAT1
31 thyroid cancer, nonmedullary, 1 28.8 GAS5 HOTAIR NEAT1
32 kidney cancer 28.7 GAS5 HOTAIR MIR27A
33 nasopharyngeal carcinoma 28.7 CDKN2B-AS1 GAS5 HOTAIR NEAT1
34 oral squamous cell carcinoma 28.4 HOTAIR MIR27A NEAT1
35 leukemia, chronic lymphocytic 12.6
36 juvenile myelomonocytic leukemia 12.5
37 hairy cell leukemia 12.5
38 megakaryocytic leukemia 12.5
39 leukemia, acute monocytic 12.4
40 adult t-cell leukemia 12.4
41 leukemia, chronic lymphocytic 2 12.4
42 t-cell prolymphocytic leukemia 12.4
43 acute lymphoblastic leukemia, childhood 12.4
44 monocytic leukemia 12.4
45 acute monoblastic leukemia 12.3
46 prolymphocytic leukemia 12.3
47 pdgfrb-associated chronic eosinophilic leukemia 12.3
48 plasma cell leukemia 12.3
49 large granular lymphocyte leukemia 12.3
50 acute erythroid leukemia 12.3

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 ABL1 BCR CEBPA ETV6 FLT3 LIF
2 hematopoietic system MP:0005397 10.15 ABL1 BCR CEBPA ETV6 FLT3 LIF
3 growth/size/body region MP:0005378 10.14 ABL1 BCR CEBPA ETV6 FLT3 LIF
4 endocrine/exocrine gland MP:0005379 10.13 ABL1 CEBPA ETV6 FLT3 LIF LIFR
5 immune system MP:0005387 10.1 ABL1 BCR CEBPA ETV6 FLT3 LIF
6 embryo MP:0005380 10.06 ABL1 ETV6 LIF LIFR NPM1 PBX1
7 mortality/aging MP:0010768 9.93 ABL1 BCR CEBPA ETV6 FLT3 LIF
8 liver/biliary system MP:0005370 9.91 ABL1 BCR CEBPA LIF LIFR NPM1
9 neoplasm MP:0002006 9.5 CEBPA ETV6 FLT3 NPM1 PML RAF1
10 normal MP:0002873 9.23 ABL1 BCR CEBPA ETV6 PBX1 PML

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
2
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
3
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
4
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
5
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
6
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
7
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
8
Clolar 18 49 CLOFARABINE Genzyme December, 2004
9
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
10
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
11
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
12
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
13
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
14
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
15
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
16
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
17
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
18
Marqibo 18 49 VINCRISTINE SULFATE Talon Therapeutics August 2012
19
Mylotarg 18 49 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
20
Neupogen 18 49 FILGRASTIM Amgen Approval April 1998
21
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
22
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
23
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
24
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
25
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
26
Trisenox 18 49 ARSENIC TRIOXIDE Cell Therapeutics September 2000
27
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 962)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
3
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
4
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1327-53-3 518740
6
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
7
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
8
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
9
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53910-25-1 439693 40926
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
11
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
12
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
13
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
14
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
16
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
19
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
20
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
21
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
22
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
24
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
26
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
27
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
28
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
29
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
30
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 320-67-2 9444
31
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
32
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
33
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4291-63-8 20279
34
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
35
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
36
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 172673-20-0 219090
37
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 6918365 151165
38
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
39 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
41
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
42
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
43
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
44
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 305-03-3 2708
45
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123948-87-8, 119413-54-6 60700
46
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
47
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
48
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
49
Ofatumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 679818-59-8 6918251
50
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 6562)
# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
3 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
4 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
6 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
10 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
11 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
12 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
13 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
14 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
15 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
16 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
17 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
18 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
19 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
20 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
21 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
22 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
23 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
24 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
25 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
26 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
27 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
28 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
29 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
30 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
31 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
32 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
33 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
34 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
35 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
36 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
37 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
38 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
39 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
40 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
41 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
42 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
43 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
44 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
45 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
46 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
47 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
48 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
49 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
50 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 29

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

41
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Nk Cells

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 41356)
# Title Authors Year
1
Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions. ( 30255571 )
2019
2
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. ( 30528805 )
2019
3
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. ( 30216644 )
2019
4
Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia. ( 30421475 )
2019
5
Bilateral trifocal IOL implantation in a pediatric case of cataract following steroid-therapy for acute lymphoblastic leukemia. ( 30555958 )
2019
6
The association between birth order and childhood leukemia may be modified by paternal age and birth weight. Pooled results from the International Childhood Cancer Cohort Consortium (I4C). ( 30098208 )
2019
7
The Association Between Childhood Leukemia and Population Mixing: An Artifact of Focusing on Clusters? ( 30247205 )
2019
8
Paraneoplastic hypereosinophilic syndrome associated with IL3-IgH positive acute lymphoblastic leukemia. ( 30207070 )
2019
9
Dysfunction of immune system in the development of large granular lymphocyte leukemia. ( 30334691 )
2019
10
Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )
2019
11
TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway. ( 30551418 )
2019
12
TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. ( 30551433 )
2019
13
The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone. ( 30551478 )
2019
14
In Vitro Cytotoxicity of Folate-Silica-Gold Nanorods on Mouse Acute Lymphoblastic Leukemia and Spermatogonial Cells. ( 30507084 )
2019
15
HIV virological failure in a patient with human T-lymphotropic virus type 1-associated leukemia. ( 30507628 )
2019
16
The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia. ( 30533380 )
2019
17
Molecular Characterization of Human Leukemia 60 (HL-60) Cells as a Model of Acute Myelogenous Leukemia Post Cryopreservation. ( 30535701 )
2019
18
Artemisinin and its derivatives: a potential treatment for leukemia. ( 30540593 )
2019
19
Purification of Leukemia-Derived Exosomes to Study Microenvironment Modulation. ( 30465207 )
2019
20
EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells. ( 30472098 )
2019
21
Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis. ( 30479190 )
2019
22
T-Cell Receptor Rearrangements Determined Using Fragment Analysis in Patients With T-Acute Lymphoblastic Leukemia. ( 30430774 )
2019
23
Impairment of Vα24-Jα18+Vβ11+ natural killer T cells in adult acute lymphoblastic leukemia patients. ( 30439366 )
2019
24
DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. ( 30382603 )
2019
25
Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia. ( 30389459 )
2019
26
Strip-dried blood sampling: applicability for bovine leukemia virus detection with ELISA and real-time PCR. ( 30412721 )
2019
27
Ex-Vivo Signal Transduction Studies in Chronic Lymphocytic Leukemia. ( 30350193 )
2019
28
Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. ( 30350194 )
2019
29
Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia. ( 30350195 )
2019
30
Analysis of Common Abnormalities Seen in Chronic Lymphocytic Leukemia Using Fluorescence In Situ Hybridization. ( 30350196 )
2019
31
Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia. ( 30350197 )
2019
32
Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. ( 30350200 )
2019
33
Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. ( 30350202 )
2019
34
Measurement of Leukemic B-Cell Growth Kinetics in Patients with Chronic Lymphocytic Leukemia. ( 30350203 )
2019
35
Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods. ( 30350209 )
2019
36
Measurement of miRNAs in Chronic Lymphocytic Leukemia Patient Samples by Quantitative Reverse Transcription PCR. ( 30350212 )
2019
37
Genome Sequencing and Analysis Methods in Chronic Lymphocytic Leukemia. ( 30350214 )
2019
38
High-Throughput Sequencing of the T-Cell Receptor Beta Chain Gene Repertoire in Chronic Lymphocytic Leukemia. ( 30350216 )
2019
39
Asparaginase products in upfront acute lymphoblastic leukemia therapy: Value, location, and style. ( 30318846 )
2019
40
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia. ( 30318867 )
2019
41
ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation. ( 30322352 )
2019
42
Role of eIF3a in 4-amino-2-trifluoromethyl-phenyl retinate-induced cell differentiation in human chronic myeloid leukemia K562 cells. ( 30340049 )
2019
43
Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan. ( 30270523 )
2019
44
FLT3 inhibitors in acute myeloid leukemia: Current and future. ( 30270754 )
2019
45
Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. ( 30280491 )
2019
46
Structure characterization and anti-leukemia activity of a novel polysaccharide from Angelica sinensis (Oliv.) Diels. ( 30290264 )
2019
47
Household exposure to pesticides and risk of leukemia in children and adolescents: Updated systematic review and meta-analysis. ( 30268646 )
2019
48
Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. ( 30105796 )
2019
49
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants. ( 30124384 )
2019
50
Osteonecrosis in children with acute lymphoblastic leukemia: A report from Children's Cancer Hospital Egypt (CCHE). ( 30183135 )
2019